Ken Griffin
AUTL

Ken Griffin’s Autolus Therapeutics AUTL Stock Holding History

Ken Griffin’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$634K Sell
459,404
-700,387
-60% -$1.06M ﹤0.01% 8717
2025
Q4 		$2.31M Sell
1,159,791
-4,884,452
-81% -$7.51M ﹤0.01% 5642
2025
Q3 		$9.85M Buy
6,044,243
+5,039,865
+502% +$9.85M ﹤0.01% 3297
2025
Q2 		$2.29M Buy
1,004,378
+815,470
+432% +$1.35M ﹤0.01% 5454
2025
Q1 		$293K Sell
188,908
-135,094
-42% -$274K ﹤0.01% 9663
2024
Q4 		$761K Buy
324,002
+20,994
+7% +$71K ﹤0.01% 7609
2024
Q3 		$1.1M Sell
303,008
-222,780
-42% -$888K ﹤0.01% 6685
2024
Q2 		$1.83M Sell
525,788
-160,692
-23% -$693K ﹤0.01% 5485
2024
Q1 		$4.38M Buy
686,480
+646,715
+1,626% +$4.03M ﹤0.01% 4143
2023
Q4 		$256K Buy
+39,765
New +$152K ﹤0.01% 9477
2023
Q3 		– Sell
-185,815
Closed -$442K – 14259
2023
Q2 		$442K Sell
185,815
-1,379,531
-88% -$3.27M ﹤0.01% 8207
2023
Q1 		$2.88M Sell
1,565,346
-211,753
-12% -$414K ﹤0.01% 4705
2022
Q4 		$3.38M Buy
1,777,099
+634,494
+56% +$1.6M ﹤0.01% 4548
2022
Q3 		$2.44M Sell
1,142,605
-1,011,052
-47% -$3M ﹤0.01% 5200
2022
Q2 		$6.09M Sell
2,153,657
-1,358,856
-39% -$4.14M ﹤0.01% 3443
2022
Q1 		$14.6M Buy
3,512,513
+1,814,570
+107% +$7.63M ﹤0.01% 2402
2021
Q4 		$8.81M Sell
1,697,943
-704,891
-29% -$4.23M ﹤0.01% 3281
2021
Q3 		$15.7M Sell
2,402,834
-359,920
-13% -$2.27M ﹤0.01% 2363
2021
Q2 		$18.3M Buy
2,762,754
+2,721,085
+6,530% +$16.9M ﹤0.01% 2187
2021
Q1 		$239K Buy
41,669
+22,661
+119% +$168K ﹤0.01% 11337
2020
Q4 		$170K Buy
19,008
+5,640
+42% +$60.1K ﹤0.01% 9853
2020
Q3 		$156K Sell
13,368
-565,976
-98% -$8.21M ﹤0.01% 8973
2020
Q2 		$9.29M Sell
579,344
-2,360
-0.4% -$26.2K ﹤0.01% 2313
2020
Q1 		$3.48M Buy
581,704
+570,163
+4,940% +$5.27M ﹤0.01% 3230
2019
Q4 		$152K Buy
+11,541
New +$151K ﹤0.01% 8354
2019
Q3 		– Sell
-71,285
Closed -$1.15M – 9137
2019
Q2 		$1.15M Buy
+71,285
New +$1.59M ﹤0.01% 5473

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ken Griffin's AUTL Position: Q1 2026 in Review

Ken Griffin reduced its Autolus Therapeutics (AUTL) stake by 60% in Q1 2026, selling an estimated $1.06M and leaving 459,404 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #8717.

Ken Griffin first reported a position in AUTL in Q2 2019 and has held it in 26 quarters since. The position peaked at $18.3M in Q2 2021. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • Ken Griffin held 459,404 shares of Autolus Therapeutics worth $634K as of Q1 2026.
  • Ken Griffin sold 700,387 Autolus Therapeutics shares in Q1 2026, an estimated $1.06M.
  • Autolus Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #8717 holding.
  • Ken Griffin first reported a position in Autolus Therapeutics in Q2 2019 and has held it in 26 quarters since.
  • Ken Griffin's Autolus Therapeutics position peaked at $18.3M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.